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levels in breast cancer patients has diagnostic
potential and correlates with molecular tumor
subtypes
Isabel Poschke1,2, Yumeng Mao1, Rolf Kiessling1 and Jana de Boniface3,4*Abstract
Background: Malignancies induce changes in the levels of serum amino acids (AA), which may offer diagnostic
potential. Furthermore, changes in AA levels are associated with immune cell function. In this study, serum AA
levels were studied in breast cancer patients versus patients with benign breast lesions.
Methods: In a prospective study, serum levels of 15 AA were measured by high performance liquid
chromatography before and after surgery in 41 breast cancer patients (BrCA) and nine patients with benign breast
lesions (healthy donors, HD). Results were analyzed in relation to clinical tumor data and tested against
immunological flow cytometry data. Principal component analysis was performed and the accuracy of AA levels as
a potential diagnostic tool was tested.
Results: Pre- but not postoperative serum AA levels were increased in BrCA in eight out of 15 AA compared with
HD. Serum AA levels were highest in the most aggressive (basal-like) as compared with the least aggressive tumor
subtype (luminal A). A principal component (PC1) of all measured AA correlated with a mainly pro-inflammatory
immune profile, while a second one (PC2, selectively considering AA preoperatively differing between HD and BrCA)
could predict health state with an area under the curve of 0.870.
Conclusions: Breast cancer shows a tumor-dependent impact on serum AA levels, which varies with intrinsic tumor
subtypes and is associated with a pro-inflammatory state. Serum AA levels need further evaluation as a potential
diagnostic tool.
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Amino acids (AA) are an integral part of most metabo-
lomics analysis. As metabolomics measure downstream
output rather than upstream gene and protein products,
they offer the opportunity of an integrated evaluation of
multiple pathways and their biological consequences [1].
Amino acid profiling has shown significant differences
in AA levels between cancer patients and healthy con-
trols [2-4], even though some of the reported findings* Correspondence: janamarit@yahoo.com
3Department of Molecular Medicine and Surgery, Karolinska Institutet,
Stockholm, Sweden
4Department of Breast and Endocrine Surgery, Karolinska University Hospital,
Stockholm, Sweden
Full list of author information is available at the end of the article
© 2013 Poschke et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.remain to be confirmed. Furthermore, AA profiling has
been shown to harbor potential as a diagnostic test, as
lately reported by a Japanese group comparing plasma
AA levels between lung cancer patients and healthy con-
trols [5].
Building on the Warburg effect [6], the metabolic shift
in tumor cells from respiration to fermentation should
result in an increased demand for and consumption of
amino acids, amongst other substances. Indeed, this has
been shown by several publications [7,8]. However, an
amino acid-rich substrate could inhibit tumor growth
by cell cycle arrest and initiation of apoptosis in a mur-
ine model [9]. These contradictory findings may welll Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Patient and tumor characteristics of 41 breast
cancer patients
Age (years) median (range) 62 (39–91)
Tumor diameter (mm) median (range) 16 (6–100)




Estrogen receptor status N (%)
Positive 33 (80.5)
Negative 8 (19.5)
Progesterone receptor status N (%)
Positive 28 (68.3)
Negative 13 (31.7)










Ki 67 in tumor cells (%) mean (sd) 24.6 (19.9)
Sentinel node result N (%)
N0 29 (70.7)
N1 12 (29.3)
Tumor intrinsic subtype N (%)
Luminal A 18 (43.9)
Luminal B 14 (34.1)
Luminal B Her2-neu positive 1 (2.4)
Her2-neu over-expressing non-luminal 2 (4.9)
Basal-like 6 (14.6)
aFluorescence in vitro hybridization, clymphovascular invasion; sd standard
deviation.
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“depletion” and the “overload” model valid.
In addition to metabolite consumption by the tumor,
it is also crucial to consider the role of amino acids for
the pro- and anti-tumorigenic effect of immune cells.
Activation of immune cells often leads to increases of
baseline amino acid requirement and immune effector
cells often rely on an external supply of certain amino
acids. Lack of AA in this situation may affect the im-
mune response negatively in several ways, including cell
division, maturation, differentiation, migration and de-
velopment of effector functions (reviewed in [10]).
We have previously shown that T lymphocytes in the
blood, lymph nodes and tumor of the present breast
cancer patient cohort expressed decreased levels of the
TCR-zeta chain, which is essential for the transduction
of stimulatory signals [11]. Others have shown that loss
of zeta-chain expression can be a result of L-arginine
(L-Arg) depletion [12,13]. Further, we observed an in-
creased number of cells expressing the L-Arg-metaboli-
zing enzyme arginase 1 in the breast cancer population
compared with controls [14]. In addition to L-Arg, other
amino acids such as tryptophan and the purine nucleoside
adenosine have been associated with the suppressive activ-
ity of immune cells. Immunomodulation may also occur
through products of amino acid catabolism, e.g. via the
IDO-GCN2, arginase and mTOR pathways [15].
In the context of the immunological evaluation of pa-
tients with early-stage breast cancer [11,14,16] we mea-
sured the serum levels of 15 different amino acids by
high performance liquid chromatography (HPLC) before
and after surgery. Results were compared with serum
samples from patients operated for benign breast lesions.
Materials and methods
Patients
This prospective study included patients with primary,
unilateral, invasive breast cancer without preoperatively
detected lymph node metastases. Sentinel lymph node
biopsy (SLNB) was performed on all patients. Details on
this patient population have previously been published
[11] and are summarized in Table 1.
As controls, individuals scheduled for surgical removal
of benign breast lesions, such as fibroadenomas or papil-
lomas, were included.
All participants provided informed written consent be-
fore inclusion. This study was approved by the Regional
Ethical Review Board at Karolinska Institutet, Stockholm.
Surgical procedure and handling of specimens
All patients were operated under general anesthesia.
Blood samples were taken before and 2–4 weeks after
surgery. Peripheral blood mononuclear cells (PBMC) were
isolated by density gradient centrifugation as describedpreviously [11]. At each time point, 5 mL blood were col-
lected in a tube without anti-coagulant. Blood was allowed
to clot for 1h, then serum was collected and additionally
purified by 15 minutes centrifugation at 1500 × g. After
centrifugation the supernatant was aliquoted and stored
at −20 degrees until further analysis.
Tumor histopathological data
Data on tumor characteristics and lymph node status
were extracted from each patient’s routine postoperative
histopathological report. For the definition of intrinsic
genomic subtypes, the surrogate parameters of estrogen
Figure 1 Inter-correlation of preoperative serum amino acid
levels. Positive correlations are angled from lower left to upper
right, negative correlations vice versa. The color indicates the R values
from R = −1 (red) over light blue to R = 1 (dark blue). The R value is
further illustrated by the roundness of the ellipse, with R = 0 a perfect
circle. (n = 50, of which n = 41 breast cancer patients (BrCA) and n = 9
healthy donors (HD)).
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and Ki67 labeling index were applied as described in the
St Gallen consensus report from 2011 [17].
High performance liquid chromatography (HPLC) and
fluorescence detection
Amino acids in plasma samples were determined by gra-
dient elution reversed-phase column liquid chromatog-
raphy with fluorescence detection following precolumn
derivatization with orthophtaldialdehyde/mercaptoetha-
nol (OPA/MCE) reagent, following minor modification
of the procedure described elsewhere [18]. Briefly, the
HPLC system included a gradient pump Spectra Physics
SP8800 (Spectra Physics, USA), a CMA/260 degasser
(CMA Microdialysis), a CMA/280 Fluorescence detector
(CMA Microdialysis) operating at excitation and emis-
sion wavelengths of 350 and 495 nm, respectively. The
derivatization reagent was prepared as follows: 27 mg
OPA were dissolved in 0.5 ml ethanol (99.5%). There-
after, 5 ml of borate buffer (0.4 M boric acid adjusted to
pH 10.4 with sodium hydroxide) were added followed by
20 μl of MCE. Typically, 10 μl samples were mixed with
10 μl of the OPA/MCE reagent by use of a CMA/200
Refrigerated Microsampler (CMA Microdialysis) equip-
ped with a 20-μl loop and operating at +6°C. After 60 s
reaction time, 10 μl volume was injected onto a HPLC
column (60 × 4 mm i.d., Nucleosil 100 C18, 5μm;
Knauer GmbH, Berlin, Germany). The mobile phase A
was a 0.03 M sodium acetate buffer (pH 6.95) containing
2.5% (v/v) of methanol and 2% (v/v) of tetrahydrofuran
and pumped at a flow rate of 1 ml/min. The amino acids
were eluted by use of a linear gradient of methanol used
as a mobile phase B and from 0 - 60% at 4 to 28 min.
Thereafter, the column was regenerated with mobile
phase A for 3 min. The chromatograms were recorded
and integrated by use of a computerized data acquisition
system (EZ Chrom data system, Scientific software Inc,
CA, USA). The chemicals were purchased from Sigma
Aldrich (St. Louis, MO, USA), methanol and tetrahydro-
furan were from Merck (Darmstadt, Germany).
Flow cytometric analysis of immunological parameters
Phenotype and functional properties of freshly isolated
PBMC were analyzed by flow cytometry as previously
described [11]. Additional file 1: Table S1 lists the anti-
body clones and staining conditions for the parameters
described herein.
Statistical methods
Prior to analysis, the distribution of all continuous var-
iables was tested using the Shapiro-Wilk test. Based on
data normality, parametric or non-parametric test op-
tions were chosen. Since median age and body mass
index (BMI) of the control population were significantlylower than in breast cancer patients, all comparisons
between the groups were adjusted for these two indepen-
dent factors by additional linear regression. Any group dif-
ferences are reported after adjustment throughout this
paper.
Differences between pre- and postoperative amino acid
levels were analyzed using the Wilcoxon signed rank test
or the paired samples t-test, respectively, for healthy do-
nors and breast cancer patients separately. The fold
change from pre- to postoperative values was then com-
pared between the two groups by linear regression, in-
cluding adjustment for age and BMI.
Due to the extensive inter-correlation of amino acid
levels (Figure 1), a principal component analysis (PCA)
was performed after testing its adequacy by Kaiser-Meyer-
Olkin measures and Bartlett’s test of sphericity.
For the analysis of covariation between the first principal
component (PC1) and continuous immunological para-
meters, bivariate correlation was tested according to
Pearson or Spearman’s rho, depending on data distribution.
A receiver operating characteristic (ROC) curve was
generated based on a second principal component, in-
cluding only those amino acids showing significant dif-
ferences between healthy women and breast cancer
patients. For the resulting PC2, its sensitivity and specifi-
city to predict health state was analyzed, and the area
under the curve (AUC) calculated.
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two groups, e.g. in different tumor histological grades or
intrinsic tumor subtypes, the Kruskal-Wallis test or
ANOVA were performed.
IBM® SPSS® Statistics 21.0 software was used for all
analyses and statistical significance was set at the 0.05
level for all tests.Results
The prospectively enrolled study population consisted of
44 patients with malignant and 11 patients with benign
breast disease. For the analysis of serum amino acids,
preoperative samples of 41 breast cancer patients and
nine patients with benign breast lesions were available;
pairs of pre- and postoperative serum values were ob-
tained from 38 and nine patients, respectively. Data
on patient and tumor characteristics are shown in
Table 1.Generation of a principal component
The marked inter-correlation of most amino acids, with
preoperative R values ranging from .339 to .974 (see
Figure 1), suggested the use of dimension reduction
which was performed using principal component analy-
sis. Kaiser-Meyer-Olkin measures of sampling adequacy
of .861 strengthened the adequacy of this procedure
together with a highly significant Bartlett’s test of sphe-
ricity (p = 0.000). The extraction of only one factor
(principal component 1, PC1), explaining 64.125% of the
total variance, was suggested by an initial scree plot.Table 2 Amino acid concentrations in preoperative serum
Amino acid Serum concentration [μg/mL]
BrCA [n = 41] HD [n = 9
Aspartic acid Asp 22.69 ± 8.4 15.14 ± 6
Glutamic acid Glu 159.98 ± 59.0 86.86 ± 27
Asparagine Asn 54.68 ± 14.8 47.96 ± 17
Serine Ser 168.34 ± 41.7 139.19 ± 4
Glutamine Gln 571.81 ± 174.3 393.82 ± 11
Citrulline Cit 41.20 ± 12.2 33.56 ± 8
Arginine Arg 162.63 ± 44.7 124.16 ± 4
Alanine Ala 571.50 ± 167.7 349.48 ± 11
Tyrosine Tyr 94.77 ± 31.3 63.18 ± 36
Valine Val 316.15 ± 68.1 205.66 ± 7
Phenylalanine Phe 91.51 ± 20.8 61.92 ± 22
Isoleucine Ile 93.77 ± 26.6 58.43 ± 24
Leucine Leu 157.89 ± 39.4 105.38 ± 4
Ornithine Orn 115.55 ± 35.5 93.53 ± 36
Lysine Lys 342.37 ± 119.9 250.04 ± 8
Serum concentrations are shown as means and standard deviations. All p-values are a
considered significant.Amino acid levels in preoperative serum are higher in
cancer patients than in healthy controls
Healthy donors (HD) had a significantly lower median
age (49 (34–63) versus 62 (39–91), p = 0.003) and body
mass index (BMI; 21.7 (19–23) versus 24.1 (17–47),
p = 0.022) than breast cancer patients (BrCA). There-
fore, all subsequent comparisons between groups were
controlled for age and BMI by linear regression.
Preoperative serum levels of eight out of 15 amino
acids (Glu, Ser, Gln, Ala, Val, Phe, Ile, Leu) were signifi-
cantly higher in breast cancer patients than healthy do-
nors (see Table 2). The same difference was true for the
PC1 (p = 0.014). This difference was absent in postopera-
tive samples in all but 2 out of 15 amino acids (Glu and
Val, see Table 3). Due to occasional high standard devia-
tions, some rather high fold differences did not reach
statistical significance.
Amino acid levels increase after surgery
Table 4 and Additional file 2: Figure S1 show the fold
changes from pre- to postoperative amino acid serum
levels for HD and BrCA separately. Twelve of 15 amino
acids levels increased significantly in both groups when
comparing pre- and postoperative values, with fold in-
creases ranging between 1.30 and 2.03. Significantly higher
fold changes in HD, after adjustment for age and BMI,
were seen in 3 out of 15 amino acids (Asp, Gln and Phe).
Pre- to postoperative fold changes were not dependent
on the extent of surgery performed as values in patients
operated with breast-conserving surgery did not differ
from values in those having a mastectomy.Fold difference P-value Trend
]
.9 1.50
.4 1.84 0.021 Higher in BrCA
.4 1.14
5.2 1.21 0.032 Higher in BrCA
3.7 1.45 0.017 Higher in BrCA
.5 1.23
7.6 1.31
9.7 1.64 0.005 Higher in BrCA
.5 1.50
5.2 1.54 0.003 Higher in BrCA
.2 1.48 0.015 Higher in BrCA
.6 1.60 0.011 Higher in BrCA
0.2 1.50 0.013 Higher in BrCA
.1 1.24
9.5 1.37
djusted for both age and BMI by linear regression. A P-value <0.05 was
Table 3 Amino acid concentrations in postoperative serum
Amino acid Serum concentration [μg/mL] Fold difference P-value Trend
BrCA [n = 38] HD [n = 10]
Aspartic acid Asp 22.51 ± 8.4 21.16 ± 7.9 1.06
Glutamic acid Glu 188.19 ± 101.8 96.71 ± 35.6 1.95 0.037 Higher in BrCA
Asparagine Asn 69.50 ± 25.3 67.43 ± 15.6 1.03
Serine Ser 220.99 ±73.4 225.64 ± 43.7 0.98
Glutamine Gln 632.40 ± 146.7 703.62 ± 126.3 0.90
Citrulline Cit 55.67 ± 19.1 43.22 ± 8.4 1.29
Arginine Arg 210.54 ± 57.8 180.39 ± 38.5 1.17
Alanine Ala 795.24 ± 257.6 648.57 ± 205.4 1.23
Tyrosine Tyr 123.16 ± 44.5 96.26 ± 25.0 1.28
Valine Val 411.64 ± 123.4 320.08 ± 35.8 1.29 0.037 Higher in BrCA
Phenylalanine Phe 117.79 ± 31.5 106.87 ± 22.4 1.10
Isoleucine Ile 118.02 ± 48.3 85.11 ± 17.5 1.39
Leucine Leu 218.70 ± 81.0 170.95 ± 35.1 1.28
Ornithine Orn 157.55 ± 44.6 160.92 ± 39.8 0.98
Lysine Lys 451.55 ± 146.7 478.04 ± 101.1 0.94
Serum concentrations are shown as means and standard deviations. All p-values are adjusted for both age and BMI by linear regression. A P-value <0.05 was
considered significant.
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between molecular tumor subtypes
Gene expression arrays have led to the identification of
fundamentally different molecular subtypes of breast
cancer [19]. For practical purposes, the 12th St Gallen
International Expert Consensus on breast cancer [17]
recently set up histopathological surrogate parametersTable 4 Changes in pre- to postoperative amino acid levels in
Amino acid Fold difference pre- to pos
BrCA [n = 38] p
Aspartic acid Asp 1.08 ± 0.51 ns
Glutamic acid Glu 1.19 ± 0.57 ns
Asparagine Asn 1.30 ± 0.43 0.000
Serine Ser 1.35 ± 0.47 0.000
Glutamine Gln 1.19 ± 0.47 ns
Citrulline Cit 1.41 ± 0.53 0.000
Arginine Arg 1.50 ± 1.23 0.000
Alanine Ala 1.44 ± 0.50 0.000
Tyrosine Tyr 1.39 ± 0.57 0.000
Valine Val 1.35 ± 0.49 0.001
Phenylalanine Phe 1.32 ± 0.39 0.000
Isoleucine Ile 1.30 ± 0.52 0.007
Leucine Leu 1.42 ± 0.49 0.000
Ornithine Orn 1.51 ± 0.78 0.000
Lysine Lys 1.61 ± 1.61 0.000
Fold differences are represented by means and SD. P-values in the respective groups re
p-values in bold style (right column) represent significant differences in fold change, ad
significant. A P-value <0.05 was considered significant.based on immunohistochemical analysis of hormone re-
ceptor status, Her2-neu amplification and proliferation
index according to Ki67 labeling. The subtypes identified
thus far (luminal A, luminal B (Her2 negative), luminal
B (Her2 positive), Her2 over-expressing (non-luminal)
and basal-like (triple negative)) differ significantly in
prognosis and prediction of treatment response.healthy donors (HD) and breast cancer patients (BrCA)
toperative P-value (group difference)
HD [n = 9] p
1.68 ± 0.81 0.013 0.049
1.20 ± 0.33 ns
1.48 ± 0.37 0.001
1.77 ± 0.65 0.000
1.89 ± 0.44 0.000 0.004
1.38 ± 0.47 0.030
1.60 ± 0.52 0.002
1.90 ± 0.58 0.000
1.75 ± 0.77 0.028
1.73 ± 0.59 0.000
1.87 ± 0.64 0.000 0.030
1.68 ± 0.72 0.003
1.81 ± 0.69 0.000
1.95 ± 0.95 0.001
2.03 ± 0.60 0.000
present the difference between pre- and postoperative value per amino acid;
justed for age and BMI, between the two groups (HD and BrCA). ns: not
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and Her2 over-expressing non-luminal (n = 2) tumors
were under-represented and thus not included in the
analysis. Comparing the remaining three subtypes, sig-
nificant differences were found in 5 of 15 amino acids
(Asn, Ala, Iso, Leu and Lys; p = 0.008, 0.041, 0.008, 0.009
and 0.043, respectively) and PC1 (p = 0.015). After fur-
ther analysis, the difference clearly resided in a marked
difference in amino acid levels between the prognostic-
ally most (luminal A, n = 18) and least (basal-like, n = 6)
favorable group. Patients with basal-like tumors had
significantly higher preoperative amino acid levels than
patients with luminal A tumors in all but three amino
acids (Asp, Gln and Glu), confirmed by PC1 (p = 0.002),
see Figure 2A and B.
There were no differences in preoperative amino acid
serum levels between different tumor stages or node-
positive versus node-negative patients.Preoperative amino acids levels correlate with
pro-inflammatory parameters
PC1 correlated with pro-inflammatory parameters mea-
sured in the same material, namely a Th1-like profile de-
fined as CCR7-CCR5 + CXCR3+ (R .418, p = 0.027) and
the production of IFN-γ and TNF-α in CD4+ T lym-
phocytes (R .419 and .402 with p = 0.003 and 0.005,
respectively). At the same time, negative correlations
with potentially suppressive subgroups of myeloid cellsFigure 2 Amino acid levels in patients with luminal A or basal-like br
component (PC) 1 values in the prognostically most (luminal A, n = 19
breast cancer.(Lin-DR-CD33+ and Lin-DR-CD34+) were observed
(R -.369 and -.384 with p = 0.008 and 0.006, respectively).
Interestingly, the expression of Fas ligand on CD8+ T
lymphocytes also showed a significant negative correlation
with PC1 (R -.626, p = 0.002).Performance of a principal component as predictive tool
of health state
For the hypothesis-generating evaluation of a potential
predictive value of amino acid levels for health state, a
second principal component (PC2) was generated, con-
taining those eight amino acids that were significantly
different between HD and BrCA preoperatively. The
mean value of PC2 was −1.12 (±0.90) for HD and 0.25
(±0.85) for BrCA (p = 0.000). A receiver operating cha-
racteristic (ROC) curve was drawn (see Figure 3). The
area under the curve (AUC) was 0.870 (95% CI 0.728-
1.000; p = 0.001), suggesting good discriminatory power.
After optimal binning of PC2 for the distinction of
health state, a cut-off value −0.75 was established. This
correctly identified 7/9 healthy women (specificity 78%)
and 37/41 breast cancer patients (sensitivity 90%), resul-
ting in a false negative rate of 9.7%.Discussion
There are few, and mostly small, studies reporting on
plasma or serum levels of amino acids, with contradic-
tory results. In 22 breast cancer patients, Kubota et al.east cancer. (A) Blood amino acid levels and (B) principal
) and least (basal-like, n = 6) favorable molecular subtypes of
Figure 3 Receiver operating characteristic curve for principal
component (PC) 2 as diagnostic tool for health state at a cut-off
value of −0.75.
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creased levels of cysteine and glutamine, but increased
levels of alanine, arginine and threonine [20]. Another
study [21] evaluated 33 breast cancer patients and ob-
served significant increases of ornithine, glutamic acid
and free tryptophan. Proenza et al. [22] demonstrated a
decreased level of aspartic acid, but increased levels of
asparagine, glutamine and hydroxyproline in 16 breast
cancer patients. Miyagi et al. could show an increase in
the plasma free amino acids threonine, serine, proline,
glycine, alanine, ornithine and lysine, and a decrease of
glutamine, tyrosine, histidine and tryptophane in 196
breast cancer patients in comparison with 976 controls
[4]. In a more recent publication from the same group,
in which the discriminative diagnostic value of AA
levels was tested, the reported predictive potential was
high enough to warrant clinical use [5]. Similarly to the
group’s earlier report, levels of individual AA were noted
to be either increased or decreased in comparison with
healthy controls, and three potential predictive indexes
were created using selected amino acids. In an extensive
metabolomics analysis on tissue samples from 271 breast
cancer patients, Budczies et al. [23] could recently show
an altered metabolic phenotype compared with normal
breast tissue. Changes in amino acid metabolism in-
volved an at least 1.9-fold increase in 16 proteinogenic
amino acids in cancerous compared with normal tissue,
unchanged levels of arginine and glutamine, and a de-
crease in asparagine. Thus, there seems to be a clear ef-
fect of breast cancer on metabolic variables, however, the
pattern of changes varies, probably owing to differentmeasurement techniques applied, lack of data adjust-
ment for potential confounders, and biological material
examined.
In the current study, reported differences between
healthy donors and breast cancer patients were rigorously
adjusted for the two potentially strong confounding fac-
tors, BMI and age. This established robust outcomes
pointing towards an independent cancer-related effect.
This assumption was supported by the fact that amino
acid levels were significantly higher in the most (basal-
like) than the least (luminal A) aggressive intrinsic tumor
subtype. In addition, 13 of 15 AA levels were indistin-
guishable between HD and BrCA after surgical tumor
removal.
Interestingly, most amino acid levels increased after
surgery. This effect was not related to the extent of sur-
gery as defined by breast-conserving surgery or lum-
pectomy versus mastectomy. One possible explanation
could be the presence of physiological postoperative in-
flammation as a part of the wound healing process. It is
unclear, however, why the increase in AA from pre- to
postoperative levels was higher in HD than BrCA. Minet-
Quinard et al., who described a normalization of three
preoperatively increased amino acids after surgical tumor
removal, did not observe any rise in amino acid levels,
however, only three amino acids were studied in this
respect [24].
Even though several publications describe changes in
amino acid levels in cancer patients versus healthy con-
trols, explanatory models are scarce. In some cancers,
decreased levels of selected amino acids have been inter-
preted as the results of high-demand tumor metabolism
associated with early signs of malnutrition. The fact that
none of the 15 measured amino acids in this study
showed decreased levels in comparison with healthy do-
nors suggests that the tumor stage in the study popula-
tion was not advanced enough for the tumor burden to
diminish the amino acid pool. This notion of a popula-
tion with mostly early-stage breast cancer is supported
by the fact that the vast majority (70.7%) was node
negative and the median tumor size was only 16 mm
(Table 1). Increased levels of serine may be explained by
the increased enzymatic activity involved in serine bio-
synthesis in tumor cells [25]. The increased glutamate
levels could be interpreted as a sign of increased glu-
tamine metabolism in the tumor, however, this does not
explain the parallel rise of glutamine [26]. Alanine, glu-
tamate, serine, glycine and aspartate may be produced
by tumor cells themselves [27]. It would clearly be of
significant interest to perform a similar analysis on the
sera of patients with late-stage breast cancer in order to
compare AA levels to the results from the current co-
hort under the assumption that more advanced disease
might instead lead to the consumption of AA.
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an important starting point of this study was the ex-
pected depletion of L-arginine through immune cells,
based on the increase in myeloid cells over-expressing
the enzyme arginase 1 in the same patient cohort [14].
However, this was not the case. The principal compo-
nent (PC1) representing preoperative AA levels corre-
lated instead with a pro-inflammatory immunological
profile. The somewhat surprising association of the PC1
with Fas-ligand expression on cytotoxic T-cells may sup-
port the earlier notion of a mixed signature of activation
and suppression in T-cells from early-stage breast cancer
patients [16].
As shown in several publications [4,28], AA levels have
the potential to be used as diagnostic tools discrimina-
ting between cancer patients and healthy subjects. The
small sample size in the present study served as a pilot
investigation showing a second principal component
(PC2) with good accuracy as a diagnostic test which
could potentially be developed further. This may serve as
a hypothesis-generating finding which needs to be vali-
dated in a larger patient cohort.Conclusions
This prospective study of 41 breast cancer patients
(BrCA) and nine healthy donors (HD) with benign breast
lesions showed significantly higher serum levels in eight
out of 15 amino acids in BrCA than HD. Increased amino
acid levels correlated with several pro-inflammatory
immunological factors and a more aggressive intrinsic
tumor subtype. Creating a principal component of sig-
nificantly different amino acids and testing it for pre-
diction of health state, a threshold value was defined
resulting in a good discriminatory power between
healthy donors and breast cancer patients with poten-
tial utility as a diagnostic test. These findings warrant
validation in a larger cohort.Additional files
Additional file 1: Table S1. Antibodies used in flow cytometry.
Additional file 2: Figure S1. Raw data analysis of all 15 serum amino
acids (A-O) in individual healthy controls (a) and breast cancer patients
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